文献速递甲状腺疾病

高风险单倍型与高非洲血统的碘难治性甲状腺癌患者独特相关

Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
PubMed 文献 · Thyroid · 2019-02-13

该研究对1145例白人患者(其中244例碘难治性)和55例非裔美国人患者(其中9例碘难治性)进行全基因组基因分型分析,发现TG、BRCA1和NSMCE2单倍型与非洲血统>80%的碘难治性非裔美国人患者独特相关。携带TG单倍型的4例患者对RAI治疗均呈生化不完全反应;携带NSMCE2单倍型的4例患者诊断时年轻且初诊即有远处转移。

要点

  • TG、BRCA1和NSMCE2单倍型与非洲血统>80%的碘难治性甲状腺癌患者独特相关。
  • 携带TG单倍型的4例患者对RAI治疗均呈生化不完全反应。
  • 携带NSMCE2单倍型的4例患者诊断时年轻且初诊即有远处转移。

核心结论

  • 识别出的候选RAI-R风险单倍型可能有助于早期分层RAI-R疾病的临床表现,进而早期干预和个性化治疗。

研究设计与样本

  • 对1145例白人患者(其中244例RAI-R)和55例非裔美国人患者(其中9例RAI-R)进行全基因组基因分型数据分析。
  • 使用参与碘代谢或DNA损伤修复的候选基因进行胚系变异关联研究,并进行全基因组关联分析。
  • 对28/55例有原发肿瘤样本的非裔美国人患者进行Sanger测序验证风险等位基因及常见体细胞突变。

主要发现

  • TG、BRCA1和NSMCE2单倍型与非洲血统>80%的RAI-R非裔美国人患者独特相关。
  • 所有携带TG单倍型的患者(n=4)对RAI治疗呈生化不完全反应。
  • 携带NSMCE2单倍型的患者(n=4)诊断时年轻(13、17、17和26岁)且初诊即有远处转移。
  • BRCA1单倍型在4例NSMCE2单倍型患者中的3例中共出现。
  • 非洲血统>80%的非裔美国人乳头状甲状腺癌中BRAFV600E发生率(3/14;21%)低于非洲血统<80%者(6/9;67%),p=0.077。

临床怎么用

  • 候选RAI-R风险单倍型可能用于RAI-R疾病临床表现的早期分层,以指导早期干预和个性化治疗策略。
  • 对候选RAI-R风险单倍型的功能注释可能揭示RAI-R疾病的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid cancer patients with radioiodine-refractory (RAI-R) disease, resulting from insufficient RAI delivery and/or RAI resistance, have increased mortality and limited treatment options. To date, studies have largely focused on tumor mutations associated with different stages of disease, which could provide prognostic value for RAI-R disease. It was hypothesized that germline variants contributing to intrinsic differences in iodine metabolism, tumor microenvironment, and/or immune surveillance are associated with RAI-R disease. METHODS: Whole-genome genotyping data analysis was performed on 1145 Caucasian (CAU) patients, 244 of whom were RAI-R, and 55 African American (AA) patients, nine of whom were RAI-R. Germline-variant association studies were conducted using candidate genes involved in iodine metabolism or DNA-damage repair, as well as genome-wide association analysis. Initial data indicated several notable variants in a small number of patients (n = 7), who were later determined to be AA patients of >80% African ancestry (n = 37). This led to the study focusing on germline single nucleotide polymorphisms uniquely associated with RAI-R AA patients. Sanger sequencing was performed to validate risk alleles and identify the incidence of the common somatic mutations BRAFV600E, NRASQ61R, and HRASQ61R in AA patients whose primary tumor samples were available (28/55). RESULTS: TG, BRCA1, and NSMCE2 haplotypes were identified as being uniquely associated with RAI-R AA patients of >80% African ancestry. All patients with the TG haplotype (n = 4) had a biochemical incomplete response to RAI therapy. Patients with the NSMCE2 haplotype (n = 4) were diagnosed at a young age (13, 17, 17, and 26 years old) with distant metastatic disease at initial diagnosis. The BRCA1 haplotype co-occurred in three out of four patients with the NSMCE2 haplotype. The incidence of BRAFV600E appears lower in papillary thyroid carcinomas from AA patients of >80% African ancestry (3/14; 21%) than in AA patients of <80% African ancestry (6/9; 67%), albeit only just approaching statistical significance (p = 0.077). The tumors available from three RAI-R AA patients were negative for BRAFV600E, NRASQ61R, and HRASQ61R. CONCLUSIONS: The identification of candidate RAI-R risk haplotypes may allow early stratification of clinical manifestations of RAI-R disease followed by early intervention and personalized treatment strategies. Functional annotation of candidate RAI-R risk haplotypes may provide insights into the mechanisms underlying RAI-R disease.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hurst Z, Liyanarachchi S, He H, et al. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid. 2019. PMID: 30654714. doi:10.1089/thy.2018.0687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。